Literature DB >> 18097452

Why perform sentinel-lymph-node biopsy in patients with melanoma?

Steven A Rosenberg.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18097452     DOI: 10.1038/ncponc1022

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


× No keyword cloud information.
  8 in total

1.  Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma.

Authors:  Ettore Minutilli; Uwe Trefzer; Eggert Stockfleth; Wolfram Sterry
Journal:  Nat Clin Pract Oncol       Date:  2009-01

2.  Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.

Authors:  Laura Calomarde-Rees; Rosario García-Calatayud; Celia Requena Caballero; Esperanza Manrique-Silva; Víctor Traves; Zaida García-Casado; Virtudes Soriano; Rajiv Kumar; Eduardo Nagore
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

Review 3.  Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.

Authors:  Yoichi Moroi
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

4.  The rationale for sentinel-node biopsy in primary melanoma.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson
Journal:  Nat Clin Pract Oncol       Date:  2008-09

5.  Survival and the sentinel lymph node in melanoma.

Authors:  Mark Faries
Journal:  Ann Surg Oncol       Date:  2010-01       Impact factor: 5.344

6.  Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy.

Authors:  T Peter Kingham; Katherine S Panageas; Charlotte E Ariyan; Klaus J Busam; Mary Sue Brady; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2010-02       Impact factor: 5.344

7.  Thick melanoma: prognostic value of positive sentinel nodes.

Authors:  Lenka Vermeeren; Fred W C van der Ent; Prapto S H Sastrowijoto; Karel W E Hulsewé
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

8.  How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?

Authors:  Merrick I Ross; Jeffrey E Gershenwald
Journal:  Ann Surg Oncol       Date:  2008-01-29       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.